The Evolving Landscape of Late-Onset Pompe Disease Management
Late-onset Pompe disease (LOPD) represents a complex clinical challenge in the field of neuromuscular medicine. As an autosomal recessive metabolic disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), it leads to the progressive accumulation of glycogen in cardiac, smooth, and skeletal muscles. While enzyme replacement therapy (ERT) has significantly altered the natural history of the disease, patients continue to experience a slow but relentless decline in motor function, characterized by proximal muscle weakness, respiratory insufficiency, and gait instability.
For the clinician, the primary difficulty lies in the quantification of this progression. Traditional tools, such as manual muscle testing (MMT), often lack the sensitivity to detect subtle changes over short clinical intervals. A recent landmark study by Maulet et al., published in Neurology, provides a much-needed longitudinal perspective on motor function changes in adults with LOPD, identifying specific biomarkers and clinical thresholds that could redefine how we monitor these patients in practice.
Highlights of the Longitudinal Assessment
The research offers several critical insights for the management of LOPD. First, it identifies hip extensor and abductor strength, alongside walking speed, as the most sensitive parameters for tracking disease progression. Second, it establishes Minimal Clinically Important Difference (MCID) thresholds, providing a benchmark for what constitutes a meaningful change in a patient’s functional status. Finally, the study highlights the pivotal role of the ankle plantar flexors in maintaining balance and a cautious gait, suggesting that distal muscle involvement may be more significant in postural stability than previously emphasized.
Study Design and Methodological Rigor
This longitudinal study followed 40 participants—20 with LOPD and 20 age-matched controls—over a period of two years. The researchers employed a comprehensive battery of assessments, moving beyond simple clinical observations to include instrumented gait analysis and dynamometry. Lower limb strength was evaluated using both clinical scales and handheld dynamometers, while gait was assessed for spatiotemporal parameters such as walking speed and single-limb stance phase. Postural control was measured through sway velocity and orientation stability.
By comparing LOPD patients against a control group, the study was able to isolate the effects of the disease from the natural processes of aging. The use of standardized response mean (SRM) and effect size calculations allowed the researchers to determine which metrics were truly responsive to change over the 24-month study period.
Key Findings: Identifying the Drivers of Functional Decline
Quantitative Muscle Strength vs. Manual Testing
One of the most significant findings was the discrepancy between manual muscle testing and quantitative dynamometry. While MMT scores showed no significant change over the two years, dynamometer assessments revealed a clear deterioration in hip extensor and abductor strength, as well as knee flexor and ankle plantar flexor strength. This suggests that the ceiling effect of MMT may be masking clinical progression in many patients, potentially delaying necessary adjustments in treatment or rehabilitation strategies.
Locomotor and Postural Control Changes
The study found that LOPD patients experienced a measurable decline in walking speed and a reduction in the single-limb stance phase of the gait cycle. These changes correlate strongly with the weakening of the hip muscles. Interestingly, postural sway velocity increased significantly in the LOPD cohort, indicating a decrease in stability that puts patients at a higher risk for falls. The researchers identified that the hip abductors are essential for lateral stability, while the plantar flexors are critical for the ‘push-off’ phase of walking and maintaining balance during standing.
Defining Clinical Meaningfulness: The Role of MCID
Perhaps the most clinically applicable aspect of the Maulet et al. study is the definition of MCID thresholds. For clinicians, knowing that a patient’s hip abductor strength has decreased is useful, but knowing whether that decrease is ‘clinically meaningful’ is essential for decision-making. The study found that a high proportion of LOPD patients exceeded the MCID for hip abductor strength and ankle plantar flexor strength over the two-year period. These thresholds provide a quantitative framework for evaluating the efficacy of current therapies and the potential benefits of emerging treatments, such as next-generation ERT or gene therapies.
Expert Commentary: Translating Data into Clinical Practice
The findings of this study underscore the necessity of incorporating objective, instrumented measurements into the routine care of LOPD patients. The sensitivity of hip strength and walking speed suggests these should be the primary endpoints in both clinical practice and future clinical trials. Furthermore, the emphasis on the plantar flexors suggests that rehabilitation programs should not only focus on proximal ‘girdle’ muscles but also incorporate distal strengthening and balance training to mitigate fall risks.
However, it is important to acknowledge the limitations of this data. The study involved a relatively small cohort and focused on a two-year window. LOPD is a heterogeneous condition, and the rate of progression can vary significantly between individuals. Further research is required to determine if these MCID thresholds remain consistent across different stages of the disease and across more diverse patient populations.
Conclusion: A New Framework for LOPD Evaluation
The study by Maulet et al. provides a robust evidence base for shifting the clinical focus in LOPD toward more sensitive and objective motor parameters. By identifying hip strength and walking speed as key determinants of decline and providing clear MCID benchmarks, this research empowers clinicians to provide more precise and proactive care. As we move into an era of more advanced therapeutic options, having the right tools to measure success—and failure—will be paramount in optimizing outcomes for those living with Late-Onset Pompe Disease.
References
1. Maulet T, Bonnyaud C, Dubois F, et al. Longitudinal Motor Function Changes in Adults With Late-Onset Pompe Disease: Key Determinants and Clinical Thresholds. Neurology. 2026;106(7):e214751. PMID: 41785434.
2. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet. 2008;372(9645):1261-1271.
3. Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319-333.